Background/aims: To compare the intraocular pressure (IOP) lowering efficacy and side effects of latanoprost 0.005% and bimatoprost 0.03% in subjects with chronic primary angle closure glaucoma (PACG).
Methods: This was an observer-masked randomized cross-over study of 60 PACG subjects who received either latanoprost or bimatoprost for 6 weeks, after which they were crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications was assessed by the reduction in IOP after 6 weeks of treatment compared to baseline.
Results: Fifty-four subjects (80 eyes) completed the study. Latanoprost reduced IOP (mean ± SD) by 8.4 ± 3.8 mmHg and bimatoprost by 8.9 ± 3.9 mmHg from a baseline of 25.2 + 3.6 mmHg and 25.2 + 3.6 mmHg respectively (p=0.23). Adverse events were mild in both groups; however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared to the latanoprost group (40%, p<0.01). Ocular irritation was the most frequently reported adverse events in both groups; 22 subjects (37.9%) treated with bimatoprost experienced ocular hyperemia as compared to 13 subjects (22.4%) treated with latanoprost (p=0.11).
Conclusions: Bimatoprost once daily was similarly effective in reducing IOP compared to latanoprost once daily in subjects with chronic PACG. Both drugs were well tolerated with mild ocular adverse events.